Neurocrine Biosciences (NASDAQ:NBIX) Given New $215.00 Price Target at Stifel Nicolaus

Posted by Geri Gentry on Aug 1st, 2026

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Stifel Nicolaus from $188.00 to $215.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently weighed in on NBIX. Piper Sandler boosted their target price on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada increased their price target on Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday. Canaccord Genuity Group lifted their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Truist Financial boosted their price objective on Neurocrine Biosciences from $155.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $199.64.

Read Our Latest Research Report on NBIX

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $166.80 on Friday. The company has a market capitalization of $16.77 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.78 and a beta of 0.39. Neurocrine Biosciences has a 52-week low of $122.14 and a 52-week high of $186.12. The company has a 50-day simple moving average of $167.81 and a two-hundred day simple moving average of $146.40.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 4,367 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $181.02, for a total value of $790,514.34. Following the completion of the transaction, the insider directly owned 16,225 shares in the company, valued at approximately $2,937,049.50. The trade was a 21.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the sale, the director directly owned 15,860 shares in the company, valued at $2,621,975.20. The trade was a 61.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 395,422 shares of company stock valued at $62,448,693. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 18.0% in the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after acquiring an additional 498,058 shares during the period. Renaissance Technologies LLC raised its stake in shares of Neurocrine Biosciences by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after purchasing an additional 180,100 shares during the period. Geode Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after purchasing an additional 34,457 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after purchasing an additional 88,522 shares during the period. Finally, Northern Trust Corp lifted its holdings in Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after purchasing an additional 295,470 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.